Actavis' Namenda switch exceeds expectations, and its ability to supply new version

Usually, exceeding expectations when it comes to a sales goal is a good thing. But in the case of Actavis ($ACT) and its forced switch of patients to a once-daily version of its Alzheimer's treatment Namenda, it is posing some problems--supply problems. The company announced earlier that it would stop production in August of the original version, a move that would leave patients no choice but to switch to the patent protected extended release product, and so keep most of the sales. It has since said it will continue to make it into the fall and conceded to Bloomberg that it is having trouble keeping up with demand for the new capsule. Story | More

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.